Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: No Condition
Interventions: CLAIR; Other
Lead sponsor: Toku Eyes Ltd; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 942 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 12,537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Cardiovascular Disease (CVD)
Interventions: Behavioral Economics Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Artery Disease
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 50 Years and older
Enrollment: 6,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 105
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: Cardiac MRI, ACC/AHA Guideline adherent care; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Royal Oak, Michigan • Jackson, Mississippi • Winston-Salem, North Carolina + 1 more

Conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
Interventions: Dynamic contrast-enhanced computed tomography, Ioversol; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: High Risk Smoldering Multiple Myeloma (HR-SMM)
Interventions: Linvoseltamab, Daratumumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 9
States / cities: Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 35 Years and older
Enrollment: 8,606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 118
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more

Conditions: Cardiovascular Disease, Atherosclerosis
Interventions: MRI, PET/MRI, Laboratory blood test; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: aripiprazole (Abilify), ziprasidone (Geodon); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Vascular Formation
Interventions: Exercise; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression
Interventions: Nimodipine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sodium Excess, Racial Disparities, Blood Pressure, Cardiovascular Risk Factor
Interventions: Low Sodium Meal (140 mg sodium chloride), High Sodium Meal (2500 mg sodium chloride); Other
Lead sponsor: Indiana University; Other
Eligibility: 19 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Auburn, Alabama • Bloomington, Indiana

Conditions: Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30,486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiovascular Risk Factor, Blood Pressure, Exercise, Diet Modification, Health Promotion
Interventions: Circuit Training exercise & Modified Mediterranean diet; Behavioral
Lead sponsor: University of New Hampshire; Other
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Obesity, Cardiovascular Risk Factor, Hyperlipidemia
Interventions: Not listed
Lead sponsor: Susan Smyth; Other
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cardiovascular Risk Factor
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 6 Months
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: Blood Sample, HEART Score; Procedure · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years and older
Enrollment: 1,572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Sacramento, California • Gainesville, Florida • Baltimore, Maryland + 3 more

Conditions: Thrombosis
Interventions: Heparin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Rochester, Minnesota • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Bone density and carotid ultrasound; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mood Disorders, Hypertension, Overweight and Obesity, Vascular Stiffness, Sleep, Elevated Blood Pressure
Interventions: Cardiovascular Assessments, Actigraphy, Laboratory assessments, Emotional/ Behavioural assessments; Diagnostic Test · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 22 Years
Enrollment: 37 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Obesity, Hypertension, Smoking
Interventions: Rimonabant, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • Catonsville, Maryland

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions: Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis; Drug · Radiation · Biological + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

CLAiR Pivotal Study

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

A Randomized Trial of Patient Financial Incentives to Reduce CVD Risk

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force

Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression

Vascular Effects of Acute Sodium (VEAS) Study

Risk Factors, Costs, and Impacts of ED Boarding

Exercise & Diet Effects on CV Risk in Firefighters

Dietary Sources of Lysophospholipids

Overcoming Obstacles in Epigenetic Analysis of Human Twins

High-Sensitivity Cardiac Troponin T to OPtimize Chest Pain Risk Stratification

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes

Association of Mood With Risk for Atherosclerosis

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies